They also listed at like 100x revenue in 2021, when they were...

They also listed at like 100x revenue in 2021, when they were recording a similarly high level of growth to EYE. I'm not surprised they've come down to a lower multiple, but I am surprised that EYE doesn't get to enjoy a revenue multiple at least a fraction of what SGHT had when they were recording strong growth. EYE is the fastest growing MIGS company with a best in class device and a strong moat. Yet it's being valued at a lower multiple than the loss making, zero growth, inferior product SGHT.

I'm confident that this will change though, it's just a matter of when. Does the market need another half of strong growth to be convinced about this company (in that case we can expect to rerate within the next few months), or will it need another two halves to be absolutely certain?